Cue Biopharma (STU:1UC) Change In Receivables : €-1.12 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cue Biopharma Change In Receivables?

Cue Biopharma's change in receivables for the quarter that ended in Mar. 2024 was €0.27 Mil. It means Cue Biopharma's Accounts Receivable declined by €0.27 Mil from Dec. 2023 to Mar. 2024 .

Cue Biopharma's change in receivables for the fiscal year that ended in Dec. 2023 was €-1.51 Mil. It means Cue Biopharma's Accounts Receivable increased by €1.51 Mil from Dec. 2022 to Dec. 2023 .

Cue Biopharma's Accounts Receivable for the quarter that ended in Mar. 2024 was €1.29 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Cue Biopharma's Days Sales Outstanding for the three months ended in Mar. 2024 was 74.39.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cue Biopharma's liquidation value for the three months ended in Mar. 2024 was €16.71 Mil.

Cue Biopharma Change In Receivables Historical Data

The historical data trend for Cue Biopharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Change In Receivables Chart

Cue Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.68

-0.55

-1.53

2.91

-1.51

Cue Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.13	-0.87	-0.49	-0.04	0.27

Cue Biopharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.12 Mil.

Cue Biopharma (STU:1UC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cue Biopharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.288	/	1.58	*	91
=	74.39

2. In Ben Graham's calculation of liquidation value, Cue Biopharma's accounts receivable are only considered to be worth 75% of book value:

Cue Biopharma's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	37.747	-	22	+	0.75 * 1.288	+	0.5 * 0
=	16.71

Cue Biopharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cue Biopharma (STU:1UC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (STU:1UC) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CUE:USA

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

Cue Biopharma (STU:1UC) Headlines

No Headlines